Safety and Potency of a High Cabergoline Dosage in Microprolactinomas

Inclusion Criteria: * 1\. Willing and able to provide written informed consent prior to any study-related procedures * 2\. Adults \>18 years old * 3\. Pre-menopausal women * 4\. Presence of signs and symptoms matching prolactinoma * 5\. Hyperprolactinemia, defined as a prolactin (PRL) level ≥2 times the local laboratory maximum level of normality, present at the time of enrolment * 6\. Presence of an identifiable pituitary mass on MRI with a maximum diameter of less than 1cm, independently of Knosp/invasiveness of the cavernous sinus * 7\. Treatment naïve * 8\. Females who engage in heterosexual intercourse must agree to use either a highly effective or a clinically acceptable method of contraception from the beginning of screening to the last study visit, which will include: * Hysterectomy or bilateral salpingectomy * Bilateral tubal occlusion or ligation * Vasectomized partner * Intrauterine device (copper or hormonal) * Progestogen-only contraception (oral, injectable or implantable) * Male or female condom with or without spermicide * Sexual abstinence (only when it is the usual and preferred lifestyle of the subject) Exclusion Criteria: * 1\. History of primary hyperparathyroidism * 2\. Use of combined hormonal contraceptive within the past 4 weeks * 3\. Pregnancy or current pregnancy desire * 4\. Prolactinoma associated with a known genetic syndrome * 5\. Familial history of pituitary adenoma * 6\. Renal failure (estimated glomerular filtration rate \<30 mL/min /1.73…